Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition.
Emanuele GiurisatoQiuping XuSilvia LonardiBrian TelferIlaria RussoAdam PearsonKatherine G FineganWenbin WangJinhua WangNathanael S GrayWilliam VermiZhengui XiaCathy TournierPublished in: Proceedings of the National Academy of Sciences of the United States of America (2018)
Owing to the prevalence of tumor-associated macrophages (TAMs) in cancer and their unique influence upon disease progression and malignancy, macrophage-targeted interventions have attracted notable attention in cancer immunotherapy. However, tractable targets to reduce TAM activities remain very few and far between because the signaling mechanisms underpinning protumor macrophage phenotypes are largely unknown. Here, we have investigated the role of the extracellular-regulated protein kinase 5 (ERK5) as a determinant of macrophage polarity. We report that the growth of carcinoma grafts was halted in myeloid ERK5-deficient mice. Coincidentally, targeting ERK5 in macrophages induced a transcriptional switch in favor of proinflammatory mediators. Further molecular analyses demonstrated that activation of the signal transducer and activator of transcription 3 (STAT3) via Tyr705 phosphorylation was impaired in erk5-deleted TAMs. Our study thus suggests that blocking ERK5 constitutes a treatment strategy to reprogram macrophages toward an antitumor state by inhibiting STAT3-induced gene expression.
Keyphrases
- signaling pathway
- cell proliferation
- pi k akt
- gene expression
- protein kinase
- adipose tissue
- transcription factor
- bone marrow
- high glucose
- dendritic cells
- acute myeloid leukemia
- diabetic rats
- cancer therapy
- squamous cell carcinoma
- working memory
- physical activity
- risk factors
- papillary thyroid
- drug induced
- immune response
- drug delivery
- oxidative stress
- nuclear factor
- endothelial cells